Show simple item record

dc.contributor.authorAlemayehu, Senait
dc.contributor.authorYigezu, Amanuel
dc.contributor.authorHailemariam, Damen
dc.contributor.authorHailu, Alemayehu
dc.description.abstractBackground: In Ethiopia, MDR-TB has become a significant public health threat; therefore, the Ministry of Health introduced two treatment approaches for MDR-TB cases: treatment initiative center (TIC) and treatment follow-up center (TFC). TIC is where patients usually are diagnosed and start the treatment. At TFC, we follow MDR-TB patients until they completed the treatment. However, there is no evidence about the cost-effectiveness of the approaches. Therefore, this study aimed to analyze the cost-effectiveness of MDR-TB treatment in TIC and TFC. Methods: In this study, we employed a full economic evaluation from a providers' perspective. We followed a hypothetical cohort of individuals from the age of 15 for a lifetime using a Markov model with five mutually exclusive health states. We used both primary and secondary data sources for the study. Ingredient-based costing approach was used. The costs include healthcare provider costs (recurrent and capital cost) and patient-side costs (direct and indirect). We use a human capital approach to estimate the indirect cost. The cost estimates were reported in the 2017 United States Dollar (US$), and effectiveness was measured using disability-adjusted life-years (DALYs) averted. Both costs and health benefits were discounted using a 3% discount rate. Both average and incremental cost-effectiveness ratios (ICER) were reported calculated. One-way and probabilistic sensitivity analyses were reported to determine the robustness of the estimates. Results: The cost per HIV negative patient successfully treated for MDR-TB was USD 8,416 at TIC and USD 6,657 at TFC. The average cost-effectiveness ratio per DALY averted at TFC was USD 671 and USD 1,417 per DALY averted at TIC. The incremental cost-effectiveness ratio (ICER) of MDR-TB treatment at TIC was USD 1,641 per DALYs averted. Conclusion: This study indicates that the treatment of MDR-TB at both TIC and TFC are cost-effective interventions compared with the willingness to pay threshold of three-times the GDP per capita in Ethiopia.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleCost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopiaen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright the authorsen_US
dc.source.journalPLOS ONEen_US
dc.identifier.citationPLOS ONE. 2020, 15 (7), e0235820.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal